Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 13 February 2007. doi:10.1136/jcp.2006.040105
Journal of Clinical Pathology 2007;60:1211-1215
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

ORIGINAL ARTICLES

Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis

Leslie R Rowe1, Brandon G Bentz2 and Joel S Bentz3

1 Institute for Clinical and Experimental Pathology, Associated Regional and University Pathologists (ARUP) Laboratories, Salt Lake City, Utah, USA
2 Division of Otolaryngology, Department of Surgery, University of Utah, Salt Lake City, Utah, USA
3 Department of Pathology, University of Utah, Salt Lake City, Utah, USA

Correspondence to:
Dr Joel S Bentz, Department of Pathology, Rm 3860, Huntsman Cancer Hospital at the University of Utah Health Sciences Center, 1950 Circle of Hope, Salt Lake City, UT 84112, USA; joel.bentz{at}hsc.utah.edu

Background: A single hotspot mutation at nucleotide 1799 of the BRAF gene has been identified as the most common genetic event in papillary thyroid carcinoma (PTC), with a prevalence of 29–83%.

Aims: To use a PCR assay to molecularly characterise the BRAF activating point mutation in a series of PTC and benign thyroid cases and correlate the mutation results with histological findings.

Methods: Formalin-fixed paraffin-embedded (FFPE) sections were evaluated for the BRAF V600E mutation using LightCycler PCR with allele-specific fluorescent probe melting curve analysis (LCPCR).

Results: 42 (37 PTC; 5 benign) surgical tissue samples were analysed for the BRAF V600E activating point mutation. Using LCPCR and direct DNA sequencing, the BRAF mutation was identified in 23/37 (62.2%) PTC FFPE samples. DNA sequencing results demonstrated confirmation of the mutation.

Conclusions: Detection of BRAF-activating mutations in PTC suggests new approaches to management and treatment of this disease that may prove worthwhile. Identification of the BRAF V600E activating mutation in routine FFPE pathology samples by a rapid laboratory method such as LCPCR could have significant value.

Abbreviations: FFPE, formalin-fixed paraffin-embedded; FNA, fine needle aspirate; FVPTC, follicular variant of PTC; LCPCR, LightCycler PCR with allele-specific fluorescent probe melting curve analysis; MAPK, mitogen-activated protein kinase; PTC, papillary thyroid carcinoma; WT, wild type


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs